Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Mar 13;96(3):296-305.
doi: 10.1136/jnnp-2024-333994.

Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study)

Sarah Passoke  1 , Carlotta Stern  1   2 , Vivien Häußler  3 , Tania Kümpfel  4 , Joachim Havla  4 , Daniel Engels  4 , Sven Jarius  5 , Brigitte Wildemann  5 , Mirjam Korporal-Kuhnke  5 , Makbule Senel  6 , Jan-Patrick Stellmann  3   7   8 , Clemens Warnke  9 , Matthias Grothe  10 , Rasmus Schülke  11 , Stefan Gingele  1 , Julian Reza Kretschmer  1 , Luisa Klotz  12 , Annette Walter  13 , Florian Then Bergh  14 , Orhan Aktas  15 , Marius Ringelstein  15   16 , Ilya Ayzenberg  17 , Carolin Schwake  17 , Ingo Kleiter  17   18 , Pia Sophie Sperber  19   20   21   22   23 , Rebekka Rust  21   22   24 , Patrick Schindler  21   22   23 , Judith Bellmann-Strobl  21   22 , Friedemann Paul  21   22   23 , Bruno Kopp  1 , Corinna Trebst #  1 , Martin W Hümmert #  25 ; Neuromyelitis Optica Study Group (NEMOS)
Collaborators, Affiliations
Observational Study

Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study)

Sarah Passoke et al. J Neurol Neurosurg Psychiatry. .

Abstract

Background: Data on cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are limited to studies with small sample sizes. Therefore, we aimed to analyse the extent, characteristics and the longitudinal course of potential cognitive deficits in patients with MOGAD.

Methods: The CogniMOG-Study is a prospective, longitudinal and multicentre observational study of 113 patients with MOGAD. Individual cognitive performance was assessed using the Paced Auditory Serial Addition Task (PASAT), the Symbol Digit Modalities Test (SDMT) and the Multiple Sclerosis Inventory Cognition (MuSIC), which are standardised against normative data from healthy controls. Cognitive performance was assessed at baseline and at 1-year and 2-year follow-up assessments. Multiple linear regression was used to analyse demographic and clinical predictors of cognitive deficits identified in previous correlation analyses.

Results: At baseline, the study sample of MOGAD patients showed impaired standardised performance on MuSIC semantic fluency (mean=-0.29, 95% CI (-0.47 to -0.12)) and MuSIC congruent speed (mean=-0.73, 95% CI (-1.23 to -0.23)). Around 1 in 10 patients showed deficits in two or more cognitive measures (11%). No decline in cognition was observed during the 1-year and 2-year follow-up period. Cerebral lesions were found to be negatively predictive for SDMT (B=-8.85, 95% CI (-13.57 to -4.14)) and MuSIC semantic fluency (B=-4.17, 95% CI (-6.10 to -2.25)) test performance.

Conclusions: Based on these data, we conclude that MOGAD patients show reduced visuomotor processing speed and semantic fluency to the extent that the disease burden includes cerebral lesions.

Keywords: COGNITION; COGNITIVE NEUROPSYCHOLOGY; NEUROIMMUNOLOGY.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SP, CStern, SJ, MK-K, VH, J-PS, MG, RS, JRK, AW, FTB, PSS and BK report no disclosures relevant to the manuscript. TK has received speaker honoraria and/or personal fees for advisory boards from Merck, Roche Pharma, Alexion/Astra Zeneca, Horizon, Chugai and Biogen. JH reports grants from the Friedrich-Baur-Stiftung, Merck and Horizon, personal fees and non-financial support from Alexion, Horizon, Roche, Merck, Novartis, Biogen, BMS and Janssen, and non-financial support from the Guthy-Jackson Charitable Foundation and The Sumaira Foundation. DE received speaker honoraria from Alexion and Horizon/Amgen. BW received grants from the German Ministry of Education and Research, Deutsche Forschungsgemeinschaft, Dietmar Hopp Foundation and Klaus Tschira Foundation, grants and personal fees from Merck, Novartis and personal fees from Alexion, INSTAND, Roche. MS has received consulting and/or speaker honoraria from Alexion, Bayer, Biogen, Bristol-Myers-Squibb, Merck, Horizon, Roche and Sanofi Genzyme. CW has received institutional support from Novartis, Alexion, Sanofi Genzyme, Biogen, Merck, Roche and Hexal. SG reports research support from Alnylam Pharmaceuticals, CSL Behring, Else Kröner Fresenius Foundation, Deutsche Forschungsgemeinschaft and Hannover Biomedical Research School (HBRS) and consulting and/or speaker honoraria from Alexion, Alnylam Pharmaceuticals, AstraZeneca, GSK, Pfizer and Merck all outside the submitted work. LK received compensation for serving on Scientific Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Genzyme, Horizon, Janssen, Merck Serono, Novartis, Roche and Viatris. She received speaker honoraria and travel support from Argenx, Bayer, Biogen, Bristol-Myers Squibb, Genzyme, Grifols, Merck Serono, Novartis, Roche, Santhera and Teva. She receives research support from the German Research Foundation, the IZKF Münster, IMF Münster, Biogen, Immunic AG, Novartis and Merck Serono. OA reports grants from the German Ministry of Education and Research (BMBF) and the German Research Foundation (DFG); grants and personal fees from Biogen and Novartis; and travel support and personal fees from Alexion, Almirall, MedImmune, Merck Serono, Roche, Sanofi, Viela Bio/Horizon Therapeutics and Zambon. MR received speaker honoraria from Novartis, Bayer Vital, Roche, Alexion, Horizon and Ipsen and travel reimbursement from Bayer Schering, Biogen Idec, Merz, Genzyme, Teva, Roche, Horizon and Merck, none related to this study. IA has received research support from Diamed and Chugai, speaking honoraria, travel grants and compensation for serving on a scientific advisory board from Alexion, Horizon, Roche, Merck and Sanofi-Aventis/Genzyme, all unrelated to this study. CSchwake has received speaker honoraria from Alexion and travel support from Novartis and UCB. All not related to the content of this manuscript. IK has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Almirall, Bayer, Biogen, GlaxoSmithKline, Hexal, Horizon, Merck, Neuraxpharm, Roche/Chugai and Sanofi. RR received speaking honorar from Roche unrelated to this study. PS received travel reimbursement by UCB. JB-S has received research support from NEMOS e.V. and Bayer AG, personal compensation from Alexion, speaking honoraria and travel grants from Bayer Healthcare, Horizon, Novartis and Sanofi-Aventis/Genzyme, in addition received compensation for serving on a scientific advisory board of Roche and Merck, all unrelated to the presented work. FP receives honoraria for lecturing, and travel expenses from Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Viela Bio, Roche, UCB, Mitsubishi Tanabe, Celgene and support for attending meetings from Alexion. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Roche, Parexel and Almirall. FP serves on advisory boards and steering committees for Celgene, Roche, UCB and Merck and is associate editor of Neurology, Neuroimmunology & Neuroinflammation and academic editor for PLoS ONE. CT has received honoraria for consultation and expert testimony from Alexion Pharma Germany. None of this interfered with the current report. MWH received research support from Myelitis e. V., speaker honoraria from selpers og, Horizon, and Alexion, and reimbursement of travel expenses and compensation for serving on an advisory board from Alexion. None of this interfered with the current manuscript.

Figures

Figure 1
Figure 1. Selection procedure and cohort characterisation of the CogniMOG-Study. Age, disease duration and EDSS are displayed as median with IQR. Female sex is displayed as percentage. The EDSS score of 10 patients was missing. This had no impact on the representativity of the group composition. EDSS, Expanded Disability Status Scale; MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease.
Figure 2
Figure 2. Mean z-scores of neuropsychological tests at baseline (patients <60 years). PASAT, Paced Auditory Serial Addition Task; SDMT, Symbol Digit Modalities Test.
See this image and copyright information in PMC

References

    1. Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. J Neuroinflamm. 2018;15:134. doi: 10.1186/s12974-018-1144-2. - DOI - PMC - PubMed
    1. Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021;20:762–72. doi: 10.1016/S1474-4422(21)00218-0. - DOI - PubMed
    1. Bruijstens AL, Breu M, Wendel E-M, et al. E.U. paediatric MOG consortium consensus: part 4 - outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:32–40. doi: 10.1016/j.ejpn.2020.10.007. - DOI - PubMed
    1. Armangue T, Olivé-Cirera G, Martínez-Hernandez E, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020;19:234–46. doi: 10.1016/S1474-4422(19)30488-0. - DOI - PubMed
    1. Azumagawa K, Nakashima I, Kaneko K, et al. A nation-wide survey of Japanese pediatric MOG antibody-associated diseases. Brain Dev. 2021;43:705–13. doi: 10.1016/j.braindev.2021.01.008. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources